Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Kappaproct Drastically Reduces the Need for Colectomy in Patients with Severe Ulcerative Colitis


- InDex Pharmaceuticals reports positive clinical data in peer-reviewed journal Inflammatory Bowel Diseases -

Stockholm, June 19, 2012 – InDex Pharmaceuticals today announced the publication of positive data from the Company's compassionate use program with its lead compound Kappaproct. In the program, eight treatment-refractory ulcerative colitis (UC) patients that had been elected for colectomy received Kappaproct, a DNA-based immunomodulatory sequence (DIMS) targeting the toll-like receptor 9 (TLR9).

The findings showed that Kappaproct induced a pronounced and rapid reduction in the colitis activity index for all treated patients within 1 week following a single intracolonic administration. Further improvements were evident at week 4, resulting in a clinical response rate after a single-dose treatment with Kappaproct of 71%, with 43% in clinical remission. By week 12, the clinical response and remission rates had reached 82% and 71%, respectively. A follow-up period of over 2 years post treatment indicated that all but one of the treated patients had avoided the need for colectomy, with the longest patient being in symptom-free remission for over 27 months.

The article “Topical Treatment with the Toll-like Receptor Agonist DIMS0150 Has Potential for Lasting Relief of Symptoms in Patients with Chronic Active Ulcerative Colitis by Restoring Glucocorticoid Sensitivity”, was published in the journal Inflammatory Bowel Diseases (DOI 10.1002/ibd.23019).

Kappaproct is currently in a European multicenter phase III trial called COLLECT (NCT01493960) for the treatment of chronic active UC patients not responding to available therapy. Results are expected for Q1 2014.

'We are very happy about the results from the compassionate use program,” said Jesper Wiklund, CEO of InDex Pharmaceuticals. “They underline the ability of Kappaproct to induce clinical remission in the most severe steroid-refractory UC patients, who have been selected for the surgical removal of parts of their colon. This provides the prospect to reduce the need for colectomy on a long-term basis. For severe ulcerative colitis patients, there is a high unmet medical need, and successful treatment with Kappaproct would dramatically improve the lives and prospects of these critically ill patients.”

About Kappaproct

Kappaproct is a single-strand, DNA-based synthetic oligonucleotide. It functions as an immunomodulatory agent by targeting TLR9. In a Phase II trial, Kappaproct has shown positive effects in the treatment of steroid resistant ulcerative colitis patients. Kappaproct has received orphan drug designation in Europe. A European multicenter Phase III study, COLLECT, is currently being conducted to evaluate the efficacy and safety of Kappaproct for the treatment of chronic active ulcerative colitis patients not responding to available therapy. More information about the study can be found on clintrials.gov with the ClinicalTrials.gov Identifier NCT01493960.


About InDex Pharmaceuticals

InDex Pharmaceuticals is a biopharmaceutical company focusing on the discovery and development of immunology-based treatments exclusively addressing disease states with a high unmet medical need. InDex Pharmaceuticals is also dedicated to personalized medicine and is developing companion diagnostics that will allow for the selection of only those patients likely to respond to a treatment. InDex Pharmaceuticals was founded in 2000 and is located in Stockholm, Sweden.

For additional information about Kappaproct and InDex Pharmaceuticals please visit www.indexpharma.com.

Contact InDex Pharmaceuticals:

Jesper Wiklund, CEO

Tel: +46 8 508 847 35/ +46 (0)733 59 05 53

jesper.wiklund@indexpharma.com


Media Inquiries:

akampion

Dr. Ludger Wess or Ines-Regina Buth

Tel.: +49 (0)40 88 16 59 64 / +49 (0)30 2363 2768

info@akampion.com


Publisher Contact Information:

InDex Pharmaceuticals
+46 8 508 847 35
jesper.wiklund@indexpharma.com

Company profile of InDex Pharmaceuticals
Past press releases of InDex Pharmaceuticals.

Data


27,526
Tech investments
From our Online Data Service
17,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Nov 8N/AOther Computers & Electronics
Nov 5€2.1MAudio/Video
Nov 5€5.2MOther Computers & Electronics
Nov 5€0.4MInternet services
Nov 5€1.3MSecurity
Nov 5€1.5MAudio/Video

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.